Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma.

McNally, Michelle A; Vangipuram, Ramya; Campbell, Matthew T; Nagarajan, Priyadharsini; Patel, Anisha B; Curry, Jonathan L; Heberton, Meghan

McNally, Michelle A; Vangipuram, Ramya; Campbell, Matthew T; Nagarajan, Priyadharsini; Patel, Anisha B; Curry, Jonathan L; Heberton, Meghan.

Afiliação

McNally MA; John P. and Katherine G. McGovern Medical School, Houston, Texas.
Vangipuram R; Department of Dermatology, John P. and Kathrine G. McGovern Medical School, Houston, Texas.
Campbell MT; Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, Texas.
Nagarajan P; Department of Pathology, MD Anderson Cancer Center, Houston, Texas.
Patel AB; Department of Dermatology, John P. and Kathrine G. McGovern Medical School, Houston, Texas.
Curry JL; Department of Dermatology, MD Anderson Cancer Center, Houston, Texas.
Heberton M; Department of Pathology, MD Anderson Cancer Center, Houston, Texas.

JAAD Case Rep ; 10: 82-84, 2021 Apr.

Article em En | MEDLINE | ID: mdl-33778141

Palavras-chave

ICI, immune checkpoint inhibitor; PNP, paraneoplastic pemphigus; anti-programmed-death-1; dermatologic toxicities; immune checkpoints inhibitors; immune-related adverse event; irAE, immune-related adverse events; paraneoplastic pemphigus; pembrolizumab; urothelial carcinoma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: JAAD Case Rep Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: JAAD Case Rep Ano de publicação: 2021 Tipo de documento: Article